[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]Deutsche Bank AG Raises Stake in Tenet Healthcare Corporation (NYSE:THC):
[TEXT]
Deutsche Bank AG lifted its holdings in shares of Tenet Healthcare Corporation (NYSE:THC – Free Report) by 4.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 79,399 shares of the company’s stock after purchasing an additional 3,351 shares during the quarter. Deutsche Bank AG’s holdings in Tenet Healthcare were worth $10,679,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in shares of Tenet Healthcare by 22.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,493,532 shares of the company’s stock worth $188,524,000 after purchasing an additional 272,906 shares during the period. AQR Capital Management LLC grew its holdings in shares of Tenet Healthcare by 20.8% during the 4th quarter. AQR Capital Management LLC now owns 872,117 shares of the company’s stock worth $110,087,000 after purchasing an additional 150,361 shares during the period. Northern Trust Corp grew its holdings in shares of Tenet Healthcare by 22.0% during the 4th quarter. Northern Trust Corp now owns 848,049 shares of the company’s stock worth $107,049,000 after purchasing an additional 152,671 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Tenet Healthcare by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 815,126 shares of the company’s stock worth $109,634,000 after purchasing an additional 13,057 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in shares of Tenet Healthcare by 45.2% during the 1st quarter. Victory Capital Management Inc. now owns 736,252 shares of the company’s stock worth $99,026,000 after purchasing an additional 229,197 shares during the period. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Get Tenet Healthcare alerts:

Insider Activity

In other Tenet Healthcare news, EVP Paola M. Arbour sold 7,738 shares of Tenet Healthcare stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $173.00, for a total value of $1,338,674.00. Following the transaction, the executive vice president directly owned 20,110 shares in the company, valued at approximately $3,479,030. This trade represents a 27.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director J Robert Kerrey sold 1,222 shares of Tenet Healthcare stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $164.96, for a total value of $201,581.12. Following the completion of the transaction, the director owned 22,377 shares in the company, valued at $3,691,309.92. This trade represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,659 shares of company stock worth $7,068,604 over the last ninety days. 0.81% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

THC has been the topic of several research reports. Bank of America increased their target price on Tenet Healthcare from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. Raymond James Financial reissued an “outperform” rating and set a $200.00 target price (up previously from $185.00) on shares of Tenet Healthcare in a research note on Wednesday, July 23rd. Mizuho increased their target price on Tenet Healthcare from $184.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, July 11th. Wall Street Zen raised Tenet Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Royal Bank Of Canada lifted their price objective on shares of Tenet Healthcare from $183.00 to $189.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $191.88.

Get Our Latest Stock Analysis on Tenet Healthcare

Tenet Healthcare Trading Down 0.2%

NYSE:THC opened at $172.04 on Friday. The stock’s 50 day moving average price is $167.18 and its 200 day moving average price is $148.40. The company has a market capitalization of $15.20 billion, a PE ratio of 11.01, a P/E/G ratio of 0.74 and a beta of 1.52. The company has a quick ratio of 1.63, a current ratio of 1.71 and a debt-to-equity ratio of 2.39. Tenet Healthcare Corporation has a 52-week low of $109.82 and a 52-week high of $185.25.

Tenet Healthcare (NYSE:THC – Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $1.18. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.16 billion. Tenet Healthcare had a return on equity of 24.69% and a net margin of 7.17%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.31 EPS. On average, research analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current year.

About Tenet Healthcare

(Free Report)

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.

See Also

Want to see what other hedge funds are holding THC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenet Healthcare Corporation (NYSE:THC – Free Report).

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/16/deutsche-bank-ag-raises-stake-in-tenet-healthcare-corporation-nysethc/

================================================================================

[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]


[TITLE]Connor Clark & Lunn Investment Management Ltd. Takes Position in Sabra Healthcare REIT, Inc. $SBRA:
[TEXT]
Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 36,210 shares of the real estate investment trust’s stock, valued at approximately $633,000.

A number of other hedge funds have also modified their holdings of the business. State of Michigan Retirement System increased its stake in shares of Sabra Healthcare REIT by 1.1% during the 1st quarter. State of Michigan Retirement System now owns 56,649 shares of the real estate investment trust’s stock worth $990,000 after purchasing an additional 600 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Sabra Healthcare REIT by 0.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 66,300 shares of the real estate investment trust’s stock worth $1,158,000 after purchasing an additional 600 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in shares of Sabra Healthcare REIT by 17.2% during the 1st quarter. Harbor Capital Advisors Inc. now owns 4,377 shares of the real estate investment trust’s stock worth $76,000 after purchasing an additional 642 shares in the last quarter. Diversify Advisory Services LLC increased its stake in shares of Sabra Healthcare REIT by 5.7% during the 1st quarter. Diversify Advisory Services LLC now owns 12,878 shares of the real estate investment trust’s stock worth $226,000 after purchasing an additional 689 shares in the last quarter. Finally, IFP Advisors Inc increased its stake in shares of Sabra Healthcare REIT by 16.2% during the 1st quarter. IFP Advisors Inc now owns 5,060 shares of the real estate investment trust’s stock worth $88,000 after purchasing an additional 706 shares in the last quarter. 99.40% of the stock is owned by hedge funds and other institutional investors.

Get Sabra Healthcare REIT alerts:

Wall Street Analyst Weigh In

SBRA has been the subject of a number of recent research reports. JMP Securities raised their price objective on shares of Sabra Healthcare REIT from $20.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Scotiabank raised their price objective on shares of Sabra Healthcare REIT from $19.00 to $20.00 and gave the stock a “sector perform” rating in a research note on Monday, June 23rd. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.00.

Sabra Healthcare REIT Stock Up 0.9%

SBRA stock opened at $18.63 on Tuesday. The stock has a market capitalization of $4.47 billion, a P/E ratio of 24.51, a PEG ratio of 1.53 and a beta of 0.86. The company has a debt-to-equity ratio of 0.91, a quick ratio of 4.80 and a current ratio of 4.80. Sabra Healthcare REIT, Inc. has a one year low of $15.60 and a one year high of $20.03. The company has a 50 day moving average price of $18.35 and a two-hundred day moving average price of $17.63.

Sabra Healthcare REIT (NASDAQ:SBRA – Get Free Report) last released its earnings results on Monday, August 4th. The real estate investment trust reported $0.38 EPS for the quarter, topping the consensus estimate of $0.36 by $0.02. The firm had revenue of $189.15 million during the quarter, compared to analysts’ expectations of $185.64 million. Sabra Healthcare REIT had a net margin of 24.87% and a return on equity of 6.69%. Sabra Healthcare REIT’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.36 EPS. As a group, sell-side analysts expect that Sabra Healthcare REIT, Inc. will post 1.45 EPS for the current year.

Sabra Healthcare REIT Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 29th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.20 annualized dividend and a dividend yield of 6.4%. Sabra Healthcare REIT’s payout ratio is currently 157.89%.
[Source link]: https://www.etfdailynews.com/2025/08/19/connor-clark-lunn-investment-management-ltd-takes-position-in-sabra-healthcare-reit-inc-sbra/


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html

================================================================================

[TITLE]Vanguard Group Inc. Acquires 1,255,594 Shares of ACADIA Pharmaceuticals Inc. $ACAD:
[TEXT]
Vanguard Group Inc. grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 9.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,203,234 shares of the biopharmaceutical company’s stock after purchasing an additional 1,255,594 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of ACADIA Pharmaceuticals worth $252,526,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wells Fargo & Company MN lifted its position in shares of ACADIA Pharmaceuticals by 7.7% during the 4th quarter. Wells Fargo & Company MN now owns 202,349 shares of the biopharmaceutical company’s stock valued at $3,713,000 after acquiring an additional 14,447 shares during the period. Cerity Partners LLC lifted its position in shares of ACADIA Pharmaceuticals by 43.2% during the 4th quarter. Cerity Partners LLC now owns 20,459 shares of the biopharmaceutical company’s stock valued at $349,000 after acquiring an additional 6,173 shares during the period. Bank of Montreal Can acquired a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at $211,000. Raymond James Financial Inc. acquired a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at $664,000. Finally, Summit Investment Advisors Inc. lifted its position in shares of ACADIA Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,519 shares of the biopharmaceutical company’s stock valued at $230,000 after acquiring an additional 795 shares during the period. 96.71% of the stock is owned by institutional investors.

Get ACADIA Pharmaceuticals alerts:

ACADIA Pharmaceuticals Stock Performance

ACAD opened at $25.06 on Tuesday. The firm has a market cap of $4.23 billion, a P/E ratio of 18.84, a PEG ratio of 6.45 and a beta of 0.70. The firm has a 50-day moving average of $22.77 and a 200 day moving average of $19.55. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $25.88.

Wall Street Analyst Weigh In

ACADIA Pharmaceuticals ( NASDAQ:ACAD Get Free Report ) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $264.57 million during the quarter, compared to analyst estimates of $263.07 million. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business earned $0.20 earnings per share. Equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the stock. BMO Capital Markets boosted their target price on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an “outperform” rating in a research report on Monday, May 19th. Bank of America boosted their target price on shares of ACADIA Pharmaceuticals from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 5th. Morgan Stanley set a $24.00 target price on shares of ACADIA Pharmaceuticals and gave the company an “equal weight” rating in a research report on Tuesday, May 20th. Citigroup reiterated an “outperform” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.88.

Check Out Our Latest Stock Report on ACADIA Pharmaceuticals

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, Director Laura Brege sold 14,446 shares of the stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total transaction of $314,633.88. Following the completion of the transaction, the director owned 15,095 shares in the company, valued at $328,769.10. This trade represents a 48.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 26.50% of the stock is owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

(Free Report)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

See Also

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report).

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/19/vanguard-group-inc-acquires-1255594-shares-of-acadia-pharmaceuticals-inc-acad/


[TITLE]Cetera Investment Advisers Increases Stake in Recursion Pharmaceuticals, Inc. $RXRX:
[TEXT]
Cetera Investment Advisers boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 22.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 75,788 shares of the company’s stock after acquiring an additional 13,955 shares during the quarter. Cetera Investment Advisers’ holdings in Recursion Pharmaceuticals were worth $401,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Ensign Peak Advisors Inc increased its position in shares of Recursion Pharmaceuticals by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock valued at $2,774,000 after buying an additional 1,300 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock worth $176,000 after acquiring an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 9.8% in the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock worth $113,000 after acquiring an additional 1,907 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares during the last quarter. Finally, QRG Capital Management Inc. boosted its stake in shares of Recursion Pharmaceuticals by 8.5% in the first quarter. QRG Capital Management Inc. now owns 28,515 shares of the company’s stock worth $151,000 after acquiring an additional 2,244 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Get Recursion Pharmaceuticals alerts:

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $5.52 on Tuesday. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $2.40 billion, a P/E ratio of -3.10 and a beta of 0.93. The stock’s fifty day moving average is $5.49 and its two-hundred day moving average is $5.81.

Analysts Set New Price Targets

Recursion Pharmaceuticals ( NASDAQ:RXRX Get Free Report ) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The business had revenue of $19.10 million during the quarter, compared to analysts’ expectations of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. Recursion Pharmaceuticals’s revenue for the quarter was up 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.40) EPS. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

A number of equities analysts have weighed in on RXRX shares. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $7.00.

View Our Latest Report on Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Profile

(Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Recommended Stories

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report).

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/19/cetera-investment-advisers-increases-stake-in-recursion-pharmaceuticals-inc-rxrx/


[TITLE]LPL Financial LLC Raises Stake in First Trust Nasdaq Pharmaceuticals ETF $FTXH:
[TEXT]
LPL Financial LLC boosted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Free Report) by 87.7% during the 1st quarter, HoldingsChannel reports. The firm owned 104,902 shares of the company’s stock after purchasing an additional 49,026 shares during the period. LPL Financial LLC owned 0.19% of First Trust Nasdaq Pharmaceuticals ETF worth $2,884,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Envestnet Asset Management Inc. lifted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 17.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 16,403 shares of the company’s stock worth $442,000 after acquiring an additional 2,384 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 13.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock worth $382,000 after acquiring an additional 1,633 shares during the period. Vivaldi Capital Management LP lifted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 15.6% in the 4th quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock worth $243,000 after acquiring an additional 1,171 shares during the period. NBC Securities Inc. lifted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 21,400.0% in the 1st quarter. NBC Securities Inc. now owns 1,075 shares of the company’s stock worth $29,000 after acquiring an additional 1,070 shares during the period. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 19.2% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 16,567 shares of the company’s stock worth $455,000 after acquiring an additional 2,663 shares during the period.

Get First Trust Nasdaq Pharmaceuticals ETF alerts:

First Trust Nasdaq Pharmaceuticals ETF Trading Up 0.5%

FTXH stock opened at $27.50 on Monday. The company has a market cap of $15.12 million, a P/E ratio of 14.51 and a beta of 0.70. First Trust Nasdaq Pharmaceuticals ETF has a 52 week low of $23.28 and a 52 week high of $29.72. The company’s 50-day moving average price is $26.27 and its 200 day moving average price is $26.32.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Thursday, June 26th were issued a dividend of $0.0892 per share. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.36 dividend on an annualized basis and a yield of 1.3%.

(Free Report)

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.

Read More

Want to see what other hedge funds are holding FTXH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Free Report).

Receive News & Ratings for First Trust Nasdaq Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust Nasdaq Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/18/lpl-financial-llc-raises-stake-in-first-trust-nasdaq-pharmaceuticals-etf-ftxh/


[TITLE]US Bancorp DE Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT):
[TEXT]
US Bancorp DE lifted its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 248.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,763 shares of the company’s stock after purchasing an additional 16,937 shares during the period. US Bancorp DE’s holdings in Phathom Pharmaceuticals were worth $149,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PHAT. Kera Capital Partners Inc. grew its holdings in Phathom Pharmaceuticals by 11.2% during the 1st quarter. Kera Capital Partners Inc. now owns 29,849 shares of the company’s stock worth $187,000 after acquiring an additional 3,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Phathom Pharmaceuticals by 18.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,149 shares of the company’s stock valued at $180,000 after purchasing an additional 3,408 shares during the last quarter. ProShare Advisors LLC raised its position in Phathom Pharmaceuticals by 36.3% during the 4th quarter. ProShare Advisors LLC now owns 14,289 shares of the company’s stock worth $116,000 after buying an additional 3,804 shares during the last quarter. GAMMA Investing LLC raised its position in Phathom Pharmaceuticals by 797.2% during the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company’s stock worth $29,000 after buying an additional 4,050 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Phathom Pharmaceuticals by 21.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,641 shares of the company’s stock worth $209,000 after buying an additional 4,592 shares during the last quarter. 99.01% of the stock is currently owned by institutional investors.

Get Phathom Pharmaceuticals alerts:

Wall Street Analysts Forecast Growth

PHAT has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Phathom Pharmaceuticals in a research report on Monday, June 9th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, June 6th. Guggenheim lowered their target price on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group reduced their price target on Phathom Pharmaceuticals from $10.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. Finally, Craig Hallum lifted their price target on Phathom Pharmaceuticals from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, June 9th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $17.50.

Phathom Pharmaceuticals Trading Down 2.2%

Shares of PHAT opened at $10.24 on Friday. The firm has a market cap of $726.47 million, a P/E ratio of -2.16 and a beta of 0.45. Phathom Pharmaceuticals, Inc. has a 12-month low of $2.21 and a 12-month high of $19.71. The company’s 50-day moving average price is $9.29 and its 200 day moving average price is $6.40.

Phathom Pharmaceuticals Profile

(Free Report)

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Further Reading

Want to see what other hedge funds are holding PHAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report).

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/17/us-bancorp-de-increases-stake-in-phathom-pharmaceuticals-inc-nasdaqphat/

================================================================================

[TITLE]Theratechnologies receives interim order in acquisition by CB Biotechnology THTX:
[TEXT]
We use cookies to improve user experience, and analyze website traffic.

For these reasons, we may share your site usage data with our analytics partners. By clicking "Accept Cookies" you consent to store on your device all the technologies described in our Cookie Policy.
[Source link]: https://thefly.com/permalinks/entry.php/id4184845/THTX-Theratechnologies-receives-interim-order-in-acquisition-by-CB-Biotechnology


[Failed to load article at https://financialpost.com/globe-newswire/theratechnologies-announces-filing-of-special-meeting-materials-and-receipt-of-interim-order-in-relation-to-its-acquisition-by-cb-biotechnology-an-affiliate-of-future-pak]


[TITLE]Theratechnologies Announces Filing of Special Meeting:
[TEXT]
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.

Board unanimously recommends shareholders vote “FOR” the Arrangement.

Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.

Visit www.theratech.com
[Source link]: https://www.globenewswire.com/news-release/2025/08/18/3134927/0/en/Theratechnologies-Announces-Filing-of-Special-Meeting-Materials-and-Receipt-of-Interim-Order-in-Relation-to-its-Acquisition-by-CB-Biotechnology-an-Affiliate-of-Future-Pak.html


[TITLE]Freeze-Thaw Bags Market Trends and Investment Opportunities to 2030 - Biotechnology and Food Storage Applications Lead the Industry:
[TEXT]
Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Freeze-Thaw Bags
[Source link]: https://www.globenewswire.com/news-release/2025/08/14/3133624/28124/en/Freeze-Thaw-Bags-Market-Trends-and-Investment-Opportunities-to-2030-Biotechnology-and-Food-Storage-Applications-Lead-the-Industry.html

================================================================================

[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html


[TITLE]Applied AI in Healthcare Market 2025-2029: Key Investment Opportunities for Treatment & Care, Administrative & Operational Efficiency, Diagnostic, and Disease Prevention & Management Applications:
[TEXT]
Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Applied AI in Healthcare Market 2025-2029" has been added to ResearchAndMarkets.com's offering.

The applied AI in healthcare market is projected to experience significant growth, with an increase of USD 75.23 billion anticipated during 2024-2029, at an impressive CAGR of 37.3%. This robust expansion highlights the market's dynamic nature and the essential role of AI in transforming healthcare operations. The report offers an up-to-date analysis of the current market scenario, emerging trends, and growth drivers, alongside a detailed vendor analysis featuring approximately 25 vendors.

Key market growth is fueled by the proliferation of big data and the growing demand for actionable insights. These insights are vital for enhancing operational efficiency and mitigating clinician burnout. Additionally, continuous advancements in AI algorithms and computational infrastructure further propel market development.

The rise of generative AI in clinical and administrative workflows, coupled with the increase in multimodal AI for comprehensive patient analysis, are highlighted as key drivers of market growth. Additionally, the proliferation of AI at the edge for point-of-care diagnostics is expected to contribute to increased market demand.

The report integrates primary and secondary information from key industry participants, providing comprehensive market size data, regional segment analysis, and vendor landscapes, along with insights into key companies involved in the market.

The applied AI in healthcare market is segmented as follows:

By Component:

Solutions

Services

By Application:

Treatment and care

Administrative and operational efficiency

Diagnostic

Disease prevention and management

By End-user:

Hospitals and clinics

Research and academic institutes

By Geographical Landscape:

North America

Europe

APAC

South America

Middle East and Africa

The report covers the following key areas:

Applied AI In Healthcare Market sizing

Applied AI In Healthcare Market forecast

Applied AI In Healthcare Market industry analysis

A detailed vendor analysis is designed to help clients bolster their market positions. The report provides an in-depth evaluation of leading vendors including AiCure, Augmedix Inc., CloudMedx Inc., and many others. Insights on upcoming trends and challenges are included to inform strategic planning and leverage growth opportunities.

A selection of companies mentioned in this report includes, but is not limited to:

AiCure

Augmedix Inc

CloudMedx Inc.

Eko Devices Inc.

Enlitic Inc.

GE Healthcare Technologies Inc.

Google LLC

International Business Machines Corp.

Koninklijke Philips N.V.

Lunit Inc.

Medtronic PLC

Microsoft Corp.

NVIDIA Corp.

Oncora Medical Inc.

PathAI Inc.

Qventus Inc.

Siemens Healthineers AG

Tempus Labs Inc.

Verantos Inc.

XpertDox LLC
[Source link]: https://www.globenewswire.com/news-release/2025/08/15/3134326/28124/en/Applied-AI-in-Healthcare-Market-2025-2029-Key-Investment-Opportunities-for-Treatment-Care-Administrative-Operational-Efficiency-Diagnostic-and-Disease-Prevention-Management-Applica.html

================================================================================

